StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$6.88−0.14 (-1.99%)

Close on Nov 18, 2026Market cap $249.69MP/E –Yield –

Evommune operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Evommune's operating income for the twelve months ending Sep 30, 2026 was -$121.89M. For fiscal 2025 it was -$81.07M.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$81.07M–
FY2024Dec 31, 2024-$70.01M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$33.33M–
Q2 FY2026Jun 30, 2026-$34.90M–
Q1 FY2026Mar 31, 2026-$23.95M–
Q4 FY2025Dec 31, 2025-$29.72M–
Q3 FY2025Sep 30, 2025-$13.33M–
Q2 FY2025Jun 30, 2025-$22.99M–
Q1 FY2025Mar 31, 2025-$15.03M–
Q4 FY2024Dec 31, 2024-$21.45M–
Q3 FY2024Sep 30, 2024-$16.52M–

More Evommune figures

See a number that looks wrong?